Last reviewed · How we verify

Etavopivat Tablets Low dose — Competitive Intelligence Brief

Etavopivat Tablets Low dose (Etavopivat Tablets Low dose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: KCNQ1 potassium channel activator. Area: Hematology/Oncology.

phase 3 KCNQ1 potassium channel activator KCNQ1 Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Etavopivat Tablets Low dose (Etavopivat Tablets Low dose) — Forma Therapeutics, Inc.. Etavopivat activates the KCNQ1 potassium channel to increase fetal hemoglobin (HbF) production in red blood cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Etavopivat Tablets Low dose TARGET Etavopivat Tablets Low dose Forma Therapeutics, Inc. phase 3 KCNQ1 potassium channel activator KCNQ1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (KCNQ1 potassium channel activator class)

  1. Forma Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etavopivat Tablets Low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/etavopivat-tablets-low-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: